m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02055)
Name
WZB-117
Synonyms
WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester
    Click to Show/Hide
Status
Preclinical
Structure
Formula
C20H13FO6
InChI
1S/C20H13FO6/c21-16-8-3-9-17(26-19(24)12-4-1-6-14(22)10-12)18(16)27-20(25)13-5-2-7-15(23)11-13/h1-11,22-23H
InChIKey
FRSWCCBXIHFKKY-UHFFFAOYSA-N
PubChem CID
46830365
TTD Drug ID
DCL8J5
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glucose transporter type 1 (SLC2A1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
References
Ref 1 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 2 Clinical pipeline report, company report or official report of Roche.